New findings point to a 6% decrease in mortality risk for each unit increase in body mass index (BMI).
For patients with idiopathic pulmonary fibrosis (IPF), having a higher body mass index (BMI) may help reduce their risk of death, according to research published in the Journal of Health, Population and Nutrition.1
In a review of 14 datasets including 2080 patients with IPF, researchers found that their risk of death decreased by 6% for every unit increase in BMI, measured in kg/m2 (HR, 0.94; 95% CI, 0.91-0.97; P < .001).
When breaking down the results by region, both Asian (HR, 0.95; 95% CI, 0.93-0.98, P = .001) and Western (HR, 0.91; 95% CI, 0.84-0.98, P = .014) groups showed similar patterns, with mean risk reductions of 5% and 9% for each unit increase in BMI, respectively.
Subgroup analyses also showed that study design did not significantly influence heterogeneity, with mean risk reductions of 5% found in retrospective cohort studies and of 11% in prospective cohort studies. Sample size also had minimal influence on heterogeneity, with smaller studies (< 100 participants) seeing risk reductions of 7% while larger studies (> 100 participants) having similar reductions of 6%.
Studies with better adjustments for confounding factors and higher quality scores demonstrated more consistent findings (HR, 0.93; 95% CI, 0.90-0.96, P < .001). Sensitivity tests confirmed the stability of the results (HR, 0.93-0.95; 95% CI, 0.90-0.96 to 0.92-0.98), and there was no significant bias in the publication data (Egger’s test, P = .159).
According to the researchers, these findings could lead to BMI becoming a clinical indicator for determining the prognosis of patients with IPF. Though, it’s important to know that increase in BMI does not necessarily mean increase in body fat, as many people associate with BMI.
“As has been suggested in patients with heart failure, higher BMI in patients with IPF may not be primarily associated with increased fat mass, but rather with increased fat-free mass (muscle mass),” the researchers explained. “This may increase oxygen consumption through increased muscle diffusion, mitochondrial respiratory capacity, and skeletal muscle strength, thereby improving exercise tolerance and cardiorespiratory fitness.”
Another theory suggests that brown adipose tissue or body fat helps reduce inflammation in the body by lowering levels of lipopolysaccharides, which trigger harmful inflammatory responses. In short, brown fat helps regulate body temperature by burning calories to generate heat, especially in cold conditions.2 Unlike white fat, which mainly stores energy and insulates organs, brown fat is more metabolically active and behaves more like lean body mass, burning stored energy to maintain body warmth and regulate blood sugar. Additionally, beige fat is a mix of white and brown fat cells that can convert white fat to brown, contributing to calorie burning.
“In addition, it may also be a possibility that the interaction between BMI and clinical symptoms in patients with IPF is influenced by disease states, such as heart failure, in which a negative correlation between BMI and poor outcomes has been described,” the researchers added.1
The study has several limitations, including the small sample sizes of the included studies, which limits the generalizability of the findings. All the studies were observational with many confounding factors, and while most performed adjustments, the inconsistency in these corrections may have overstated the link between BMI and mortality risk. Additionally, due to limited data, the meta-analysis could not evaluate associations between different BMI categories or levels of BMI change and mortality risk. Future research should focus on addressing these gaps.
References
Low Pulmonary Rehabilitation, Palliative Care Referrals for Patients With IPF Persist
October 30th 2024Despite proven benefits, referrals to pulmonary rehabilitation and palliative care for patients with idiopathic pulmonary fibrosis (IPF) in England remain significantly lower than for other respiratory conditions.
Read More
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Early Intervention, Targeted Strategies Needed to Improve Disparities, Survival in Patients With IPF
October 17th 2024Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).
Read More
Racial, Ethnic Disparities Persist in the Treatment, Hospitalization of Patients With IPF
October 15th 2024Two posters presented at CHEST 2024 revealed significant racial and ethnic disparities in the hospitalization and treatment of patients with idiopathic pulmonary fibrosis (IPF), with Black patients hospitalized at younger ages but less likely to receive antifibrotic medications than White patients.
Read More